Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes.

Scientific reports - 29 Jan 2020

Li Huili, Zhang Qingzhao, Shuman Lauren, Kaag Matthew, Raman Jay D, Merrill Suzanne, DeGraff David J, Warrick Joshua I, Chen Guoli

Abstract excerpt

Although advanced bladder cancer overall has a poor prognosis, a subset of patients demonstrate durable response to immune checkpoint inhibitors. Evidence shows that the response to checkpoint inhibitors may be associated with type and degree of immune infiltration in the tumor microenvironment. Here, we evaluated immune markers stratified by molecular subtypes and histologic variants. The study utilized a series...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Differentiation, Myelomonocytic
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Pharmacological

Share to CD3 Complex

Share to CD8 Antigens

Share to Lymphocytes, Tumor-Infiltrating

Share to Programmed Cell Death 1 Receptor

Share to Urothelium

Source

Open in PubMed Open full text

Identifiers

PMID: 31996725
DOI: 10.1038/s41598-020-58351-6
PMCID: PMC6989654

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes.PMID 31996725Read ↗

Bladder Cancer Exhibiting High Immune Infiltration Shows the Lowest Response Rate to Immune Checkpoint InhibitorsSemantic proximity Read ↗

Analysis of tumor microenvironment characteristics in bladder cancer: implications for immune checkpoint inhibitor therapySemantic proximity Read ↗

Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial CarcinomasSemantic proximity Read ↗

A Methylation-Based Reclassification of Bladder Cancer Based on Immune Cell GenesSemantic proximity Read ↗

STAT1 is a key gene in a gene regulatory network related to immune phenotypes in bladder cancer: An integrative analysis of multi-omics data.Semantic proximity Read ↗

Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.Semantic proximity Read ↗

In silico analysis of the immune microenvironment in bladder cancerSemantic proximity Read ↗

A B cell-derived gene expression signature associates with an immunologically active tumor microenvironment and response to immune checkpoint blockade therapySemantic proximity Read ↗

Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.Semantic proximity Read ↗

Histopathologic, Molecular, and Clinical Profiling of Lymphoepithelioma-like Carcinoma of the Bladder.Semantic proximity Read ↗

Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.Semantic proximity Read ↗

Profiles of Immune Infiltration in Bladder Cancer and its Clinical Significance: an Integrative Genomic Analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.